Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued
Cencora (COR) drew fresh attention after its latest earnings release, which showed quarterly revenue of $78.36 billion. This figure was up 3.8% year on year but about 3.9% below consensus forecasts.
See our latest analysis for Cencora.
Cencora’s share price has recently picked up, with a 1-day share price return of 0.89%, a 7-day share price return of 2.54%, and a 1-month share price return of 8.68%. However, the share price is still down 9.66% year to date, while the 5-year total shareholder return of 186.24% highlights how longer term holders have seen a very different experience.
If Cencora’s latest earnings have you rethinking what you own, it could be a good moment to broaden your search and check out 40 healthcare AI stocks
Cencora now trades at a sizeable discount to both its estimated fair value and analyst targets after a softer revenue quarter and mixed share performance this year. Is the market’s caution sensible, or is it starting to look excessive?
Most Popular Narrative: 12.7% Undervalued
Cencora’s most followed valuation narrative places fair value at $350.58 per share versus the latest close of $306.13, framing the stock as trading below that assessment and tying the story closely to long term earnings power.
Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.
Want to see what underpins that fair value gap? The narrative leans heavily on compounding revenue, margin shifts, and a richer earnings mix. The full breakdown connects these moving parts into one valuation story.
Result: Fair Value of $350.58 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Cencora’s story can change quickly if regulatory scrutiny tightens drug pricing or if margin pressure from generics and biosimilars proves more persistent than expected.
Find out about the key risks to this Cencora narrative.
Next Steps
With Cencora’s mixed signals in mind, it makes sense to weigh both sides quickly and ground your own view in the underlying numbers by checking the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Cencora?
Do not stop with Cencora. Broaden your opportunity set now by testing different angles so you do not miss stocks that better match your risk and return goals.
- Target potential mispricings by scanning for companies that combine quality with attractive valuations using the 46 high quality undervalued stocks
- Strengthen your income lineup by focusing on companies with substantial yields and resilient cash flows through the 8 dividend fortresses
- Prioritize resilience by zeroing in on companies with lower risk profiles and sturdier fundamentals via the 80 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com